antiretroviral medication will be considered only if the medication
is approved by the U.S. Food and Drug Administration and is used in
accordance with an acceptable drug therapy protocol. Acceptable
protocols are cited in Guidelines for the Use of Antiretroviral
Agents in HIV Infected Adults and Adolescents developed by the
Department of Health and Human Services Panel on Clinical Practices
for Treatment of HIV Infection.
Followup evaluations of applicants granted certification will include quarterly determinations of viral load by PCR, a CD4+ cell count, and the results of other laboratory and clinical tests deemed appropriate by the treating physician. These will be included in a written status report provided by the treating physician every 6-months. In addition, the results of cognitive function studies will be required at annual intervals for medical clearance or medical certification of ATCS’s and first- and second-class applicants. Third-class applicants will be required to submit cognitive function studies every 2 years. Adverse clinical findings, including significant changes in cognitive test results or an increased viral load exceeding 5,000 copies per milliliter shall constitute a basis for withdrawing medical certification. Exceptions, if any, will be based on individual consideration by the Federal Air Surgeon.